文献速递心力衰竭与心肌病心律失常冠心病

在心脏再同步治疗基础上依据心肌病变类型加用除颤治疗的疗效观察

Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

该多中心观察性研究纳入5,307例无持续性室性心律失常病史、接受CRT植入的心衰患者,比较加用ICD与不加用ICD的结局。结果显示,缺血性心肌病患者加用ICD后生存获益更优(HR 0.76,95%CI 0.62–0.92,P=0.005),而非缺血性扩张型心肌病患者未见显著差异(HR 0.92,95%CI 0.73–1.16,P=0.49)。

要点

  • 缺血性心肌病患者在CRT基础上加用ICD与更低死亡率相关(HR 0.76)。
  • 非缺血性扩张型心肌病患者加用ICD未见显著生存获益(HR 0.92)。
  • 非缺血性扩张型心肌病未除颤者的超额死亡中仅0.4%归因于心脏性猝死。

核心结论

  • 在接受CRT的心衰患者中,非缺血性扩张型心肌病患者可能不会从额外的一级预防ICD治疗中获益,而缺血性心肌病患者则可能获益。

研究设计与样本

  • 该研究为观察性、多中心、欧洲队列研究,纳入5,307例连续的无持续性室性心律失常病史的DCM或ICM患者,均接受CRT植入,其中加用除颤器者4,037例、未加用者1,270例。
  • 研究采用倾向性评分和死因分析比较结局。

主要发现

  • 平均随访41.4±29.0个月后,ICM患者接受CRT加除颤器较未加除颤器者生存更优(经倾向性评分及所有死亡预测因素调整的死亡风险比:0.76;95%CI:0.62–0.92;P=0.005),而DCM患者未见此种差异(风险比:0.92;95%CI:0.73–1.16;P=0.49)。
  • 与接受除颤器者相比,未接受除颤器者的超额死亡中,ICM患者有8.0%与心脏性猝死相关,而DCM患者仅0.4%与心脏性猝死相关。

临床怎么用

  • 对于有CRT适应症的心衰患者,缺血性心肌病患者在CRT基础上加用一级预防ICD可能带来生存获益。
  • 对于非缺血性扩张型心肌病患者,在CRT基础上加用一级预防ICD可能不带来获益。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with nonischemic dilated cardiomyopathy (DCM) may be at lower risk for ventricular arrhythmias compared with those with ischemic cardiomyopathy (ICM). In addition, DCM has been identified as a predictor of positive response to cardiac resynchronization therapy (CRT). OBJECTIVES: The aim of this study was to investigate the impact of an additional implantable cardioverter-defibrillator over CRT, according to underlying heart disease, in a large study group of primary prevention patients with heart failure. METHODS: This was an observational, multicenter, European cohort study of 5,307 consecutive patients with DCM or ICM, no history of sustained ventricular arrhythmias, who underwent CRT implantation with (n = 4,037) or without (n = 1,270) a defibrillator. Propensity-score and cause-of-death analyses were used to compare outcomes. RESULTS: After a mean follow-up period of 41.4 ± 29.0 months, patients with ICM had better survival when receiving CRT with a defibrillator compared with those who received CRT without a defibrillator (hazard ratio for mortality adjusted on propensity score and all mortality predictors: 0.76; 95% confidence interval [CI]: 0.62 to 0.92; p = 0.005), whereas in patients with DCM, no such difference was observed (hazard ratio: 0.92; 95% CI: 0.73 to 1.16; p = 0.49). Compared with recipients of defibrillators, the excess mortality in patients who did not receive defibrillators was related to sudden cardiac death in 8.0% among those with ICM but in only 0.4% of those with DCM. CONCLUSIONS: Among patients with heart failure with indications for CRT, those with DCM may not benefit from additional primary prevention implantable cardioverter-defibrillator therapy, as opposed to those with ICM.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Barra S, Boveda S, Providência R, et al. Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. J Am Coll Cardiol. 2017. PMID: 28359511. doi:10.1016/j.jacc.2017.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。